I-Mab (IMAB) completes Phase 1b givastomig enrollment in 1L gastric cancer

Rhea-AI Filing Summary

I-Mab submitted a Form 6-K that makes a new press release part of several existing registration statements on Form F-3 and Form S-8. This means the information in the press release is now formally included in the company’s U.S. securities offering documents.

The incorporated press release announces that I-Mab has completed enrollment in its planned Phase 1b dose expansion study of givastomig in combination with immunochemotherapy for patients receiving first-line treatment for gastric cancers. Completing enrollment is an early clinical milestone that allows the study to move fully into the data-collection and analysis phase.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-39173

I-MAB

2440 Research Boulevard, Suite 400

Rockville, MD 20850

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒                Form 40-F ☐

DOCUMENTS INCORPORATED BY REFERENCE

Exhibit 99.1 set forth in this Form 6-K shall be deemed to be incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File No. 333-239871, File No. 333-256603, File No. 333-265684 and File No. 333-279842) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release - I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	I-MAB
	By	:	/s/ Joseph Skelton
	Name	:	Joseph Skelton
	Title	:	Chief Financial Officer

Date: August 11, 2025

FAQ

What does I-Mab (IMAB) report in this Form 6-K?

The company submits a Form 6-K to furnish a press release as Exhibit 99.1 and to incorporate that press release into its existing Form F-3 and Form S-8 registration statements.

What clinical milestone does I-Mab (IMAB) disclose for givastomig?

The press release states that I-Mab has completed enrollment in a planned Phase 1b dose expansion study of givastomig in combination with immunochemotherapy.

Which patient group is targeted in I-Mab's Phase 1b givastomig study?

The study involves givastomig in combination with immunochemotherapy in patients receiving first-line (1L) treatment for gastric cancers.

How is the givastomig press release used in I-Mab’s SEC registrations?

Exhibit 99.1 is deemed incorporated by reference into I-Mab’s Form F-3 and several Form S-8 registration statements, becoming part of those offering documents from the date the Form 6-K is furnished.

Does the Form 6-K describe detailed clinical results for givastomig?

The content indicates that enrollment in the Phase 1b dose expansion study has been completed, but it does not provide specific efficacy or safety results in this excerpt.